A new report accuses American drugmaker Moderna of prioritizing profits from COVID-19 vaccines by keeping poor countries waiting. The New York Times says the vaccine maker has sold most of its doses to wealthier nations. Only one million doses have gone to low-income countries...
Moderna says its COVID-19 vaccine strongly protects kids as young as 12. The company released the preliminary findings Tuesday based on testing on more than 3,700 12- to 17-year-olds in the United States.
WASHINGTON - Drugmaker Moderna asked the Food and Drug Administration on Thursday to authorize a fourth shot of its COVID-19 vaccine as a booster dose for all adults.The request is broader than rival pharmaceutical company Pfizer's request earlier this week for the regulator to approve a...
Moderna said it is looking at whether a booster shot – either of its existing vaccine or of a new shot designed to protect against the South Africa variant – could be made available in future if evidence were to emerge that protection against the virus deteriorated over time....
symptomatic—adj.relating to or showing symptoms of a disease participant—n.a person who is involved in an activity or event : a person who participates in an activity or event mild—adj.gentle in nature or behavior ...
The Swiss drugmaker also produces ingredients for Moderna in the United States. Sweden's Recipharm, Samsung Biologics as well as ThermoFisher , which inked a deal with Moderna this week, also have roles in making the shot.
Moderna COVID-19 clinical considerations. (Source: RI DoH) The two vaccines are very similar and both are based on mRNA technology, but there are some important differences. The Pfizer vaccine is approved for patients age 16 and older, while the Moderna vaccine is approved for patients age 18...
The Moderna COVID-19 Vaccine has emergency authorization from the FDA for active immunization to prevent COVID-19 in individuals 18 and older. The vaccine uses a new technology; synthetic mRNA directs the body to create harmless virus proteins to train y
company Moderna submitted a request to the U.S. Food and Drug Administration (FDA) on Thursday for emergency use authorization (EUA) on a fourth dose of its COVID-19 vaccine for adults 18 years of age and older, who already received a booster dose of any approved or authorized shot. ...
Moderna's new version of its COVID-19 vaccine, which targets two virus variants including Omicron, has outperformed the company's original Spikevax shot in a head-to-head clinical trial. mRNA-1273.214 stimulated almost twice the neutralising antibody lev